ଝ Please cite this article as: Meza-Junco J, Montano-Loza AJ. El cáncer gástrico en México: mejoría, pero aún con mucho por hacerse. Revista 60% of GC, 6 and more than 5% of all cancer worldwide. 7 Moreover, treatments to eradicate H. pylori infection in asymptomatic subjects have been shown to decrease the frequency of both precancerous gastric lesions and GC in Asian countries. 8 This study also highlights the fact that GC is an aggressive disease with a high mortality rate, and that the majority of GC patients in clinical practice have advanced disease at diagnosis. Despite the progress made in diagnosis, surgical techniques, chemotherapy, and radiotherapy, prognosis for GC remains poor.
Currently, in rural areas in North America with an increased incidence of H. pylori infection and GC, 9 there are working groups whose goal is to identify effective treatment strategies and develop recommendations for health policy aimed at management of H. pylori infection and reduction of GC. In addition, screening for GC could be useful in detecting asymptomatic patients with early GC in high-prevalence areas, 10 which, in turn, would increase the number of treatable cancers and improve overall survival. Therefore, the adoption of such strategies should be considered for areas in Mexico with a high prevalence of GC.
In conclusion, despite the reduction in the incidence of GC in Mexico comparable to the decrease in incidence worldwide, 7 this disease continues to be a major health problem in Mexico, with a significantly negative social impact from the premature deaths caused by GC. Three major potential areas for development should be recognized: 1) Improved sanitation and access to potable water could result in a further reduction of prevalence of H. pylori infection and GC; 2) GC screening for early recognition of high-risk patients for GC, 11 such as those with atrophic gastritis, intestinal metaplasia, gastric ulcer, or dysplasia, especially in areas with the least favorable education, occupation, health, housing, and employment conditions; and 3) Improvements in GC therapy, which are expected as our understanding of GC biology and signaling pathways improves. The integration of targeted therapies is already possible and early results are promising. Better EDITORIAL therapy selection for individual patients may also significantly improve treatment and patient survival.
